Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02074800 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants

A Phase 1 study of Healthy, sponsored by Centocor.

Completed
Registry status
Phase 1
Development phase
145
Enrollment target
2
Study locations

NCT02074800: Completed Phase 1 study of Healthy, sponsored by Centocor.

NCT02074800 is a Phase 1 study of Healthy that has completed, run by Centocor. The registered enrollment target is 145 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (78% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02074800, a Phase 1 study of Healthy, has completed, sponsored by Centocor.

COMPLETED
Registry status
Phase 1
Development phase
145 participants
Enrollment target
2
Study locations

Study Summary

The purpose of Part 1 of this study is to assess the safety and tolerability of 2 dose levels (1.4 and 2.8 mg/kg) of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328. The purpose of Part 2 of this study is to access the pharmacokinetics (what the body does to the study medication) comparability of the 1.4 mg/kg dose of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328.

Conditions Studied

Healthy

Interventions

  • DRUG Placebo
  • DRUG CNTO 328 (Sp2/0-derived)
  • DRUG CNTO 328 (CHO-derived)

Study Locations (2)

Nebraska

  • - Lincoln

New Jersey

  • - Neptune City

Trial Details

FieldValue
Enrollment Target 145 participants
Start Date 2008-06
Est. Completion 2009-06
Phase Phase 1
Centocor

33 total trials

What the finished NCT02074800 record still lists

NCT02074800 is an interventional study that assigns participants to a tested intervention. The registered 145 participants enrollment target is mid-sized for trials with a published cap, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (78% lower).

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02074800 reports a single indexed study location in Nebraska, New Jersey.

Frequently Asked Questions

What is clinical trial NCT02074800 about?

NCT02074800 is a clinical study titled "A Study to Assess the Safety and Pharmacokinetics of a Single Intravenous Administration of CNTO 328 Derived From 2 Different Cell Lines in Healthy Participants". The purpose of Part 1 of this study is to assess the safety and tolerability of 2 dose levels (1.4 and 2.8 mg/kg) of CHO-derived CNTO 328 and Sp2/0-derived CNTO 328. The purpose of Part 2 of this study is to access the pharmacokinetics (what the body does to the study medication) comparability of th...

What is the current status of trial NCT02074800?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 145 participants. The study started on 2008-06. Estimated completion is 2009-06.

What conditions does trial NCT02074800 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT02074800?

The interventions under investigation include: Placebo (DRUG), CNTO 328 (Sp2/0-derived) (DRUG), CNTO 328 (CHO-derived) (DRUG).

Who is sponsoring clinical trial NCT02074800?

This trial is sponsored by Centocor, which has 33 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02074800 being conducted?

This trial has 2 study locations across Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02074800's enrollment target sits among peer trials

145 159th of 1090 higher than 931 of 1,090 other Healthy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02688959 · 145 participants · NA

    Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)

  • NCT03586609 · 145 participants · Phase 2

    Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

  • NCT03767595 · 145 participants · NA

    ProACT Post-Approval Study

  • NCT03808337 · 145 participants · Phase 2

    Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT02074800, the US trial registry maintained by the National Library of Medicine. NCT02074800 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.